Compound Profile
Icariin
Compound profile with evidence, safety, and practical fit.
Last reviewed:
C PreliminaryMonograph visual
Icariin
Generated profile category visual
Where to go next — guides & comparisons
Continue reading
- If you want to browse more compounds → All compounds
Quick Stats
Evidence level
Limited evidence
Typical onset
Varies by prep
Safety rating
Standard caution: Safety review pending
Best for
PDE5 NO
Found In
Botanicals that contain Icariin, with full herb profiles.
Safety & Cautions
Limited human safety data available
Evidence Summary
C PreliminaryEvidence lens
Early signal that needs stronger human replication before practical claims.
PreliminaryLimited evidence
Human clinical evidence: Present in source signals
Mechanistic / preclinical: Mechanism mapped — Angiogenic Pathway Modulation · Endothelial Function Support · Nitric Oxide Signaling Enhancement
Research maturity: Preliminary or mixed — main contexts: PDE5 NO
Safety boundary: Safety note available — Limited human safety data available
Evidence Strength
Confidence estimate based on the design quality and consistency of published clinical trials.
Icariin has a limited evidence evidence rating.
General wellnessGeneral wellness
Effects
1
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
A
Strong
Multiple RCTs, consistent direction, adequate effect size
B
Moderate
Some RCTs or consistent observational data in humans
C
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
D
Traditional / Theoretical
Traditional use only; no controlled human trials
How Icariin Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How Icariin Works
CompoundTarget / ReceptorMechanismEffect / Outcome
Mechanisms & Biological Pathways▼
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
Angiogenic Pathway ModulationEndothelial Function SupportNitric Oxide Signaling EnhancementCGMP Mediated VasodilationVascular Function SupportPDE5 Inhibition
Condition guides
Continue exploring
Related research paths
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Review available sources for Icariin
Independent database mapping — evaluated separately from safety and efficacy scores.
Affiliate Disclosure: Shopping links may earn this site a commission at no cost to you. Links are chosen on quality and availability, never commission tiers; safety warnings and evidence ratings stay independent.
Related alternatives
Herbs for similar conditions
Tradeoffs
Free safety checklist
Get the Icariin evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Compound profile context
How to interpret Icariin
Icariin dosage by use case, onset and duration, safety limits, and interactions for pde5 no, graded against research. Limited Human Evidence research evidence. Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.
When reviewing Icariin, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.
For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.